The PBAC will consider limiting and potentially even removing MSD's PD-L1 immunotherapy from subsidy for patients with advanced lung cancer unless the company agrees to a price cut. …
Latest Video
New Stories
-
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News